Li Fraumeni syndrome in the UK: clinical characteristics and outcomes of TP53 carriers
Individuals with LFS have a high risk of cancer, cancer recurrence, and death. Larger multicentric international studies focusing on developing cohorts of specific diseases are needed to better understand disease patterns related to different pathogenic TP53 variants and inform which patients with LFS may need a more targeted and aggressive surveillance protocol.
Authors
- Rosalind A. Eeles (ORCID: https://orcid.org/0000-0002-3698-6241)
- Zoe Kemp (ORCID: https://orcid.org/0000-0003-2692-0369)
- Christopher M. Bunce (ORCID: https://orcid.org/0000-0003-4084-8973)
- Jui-Hung Weng (ORCID: https://orcid.org/0000-0001-8349-3995)
- A. George
- Caroline S. Clarke (ORCID: https://orcid.org/0000-0002-4676-1257)
- S. Sardo Infirri
- Terri Patricia McVeigh (ORCID: https://orcid.org/0000-0001-9201-9216)
- Richard Lee (ORCID: https://orcid.org/0000-0002-9480-6843)
- Erin Finn (ORCID: https://orcid.org/0000-0002-0994-5743)
Institutions
- Royal Marsden NHS Foundation Trust (GB)
- Royal Marsden Hospital (GB)
- University College London (GB)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-08-21
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105541
- Citations
- 1
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Royal Marsden NHS Foundation Trust
- National Institute for Health and Care Research
- Samsung Biomedical Research Institute